Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -30.08% is 19% above its 5-year average of -37.15%, around the middle of its 5-year range (-50.91%–-17.32%).
35.20% above its 12-month average of -46.42%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -7.76%.
RETURN ON ASSETS (ROA)
-30.08%
RETURN ON ASSETS (ROA) AVG TTM
-46.42%
RETURN ON ASSETS (ROA) AVG 3Y
-46.30%
RETURN ON ASSETS (ROA) AVG 5Y
-37.15%
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
+35.20%
CURRENT VS 3Y AVG
+35.03%
CURRENT VS 5Y AVG
+19.02%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-28.55%
median of 582 covered companies
CURRENT VS SECTOR MEDIAN
-5.36%
vs the sector median at left
Allogene Therapeutics, Inc.
Market Cap
$498.75M
Return on Assets (ROA)
-30.08%
TTM Avg
-46.42%
3Y Avg
-46.30%
5Y Avg
-37.15%
Market Cap
$507.55M
Return on Assets (ROA)
-13.22%
TTM Avg
-17.80%
3Y Avg
-57.37%
5Y Avg
-51.87%
Market Cap
$513.25M
Return on Assets (ROA)
-17.46%
TTM Avg
-32.28%
3Y Avg
-24.08%
5Y Avg
-18.67%
Market Cap
$516.46M
Return on Assets (ROA)
-17.40%
TTM Avg
-49.85%
3Y Avg
-45.66%
5Y Avg
-41.17%
Market Cap
$521.76M
Return on Assets (ROA)
-16.69%
TTM Avg
-61.13%
3Y Avg
-63.72%
5Y Avg
-100.27%
Market Cap
$473.57M
Return on Assets (ROA)
-13.84%
TTM Avg
-22.27%
3Y Avg
-29.75%
5Y Avg
-35.86%
Market Cap
$473.36M
Return on Assets (ROA)
-8.14%
TTM Avg
-30.20%
3Y Avg
-72.84%
5Y Avg
-64.85%
Market Cap
$471.65M
Return on Assets (ROA)
1.38%
TTM Avg
-14.74%
3Y Avg
-19.98%
5Y Avg
-18.10%
Market Cap
$471.20M
Return on Assets (ROA)
-22.99%
TTM Avg
-20.77%
3Y Avg
-18.00%
5Y Avg
-22.63%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Allogene Therapeutics, Inc. (ALLO) | $498.75M | -30.08% | -46.42% | -46.30% | -37.15% |
| Monopar Therapeutics Inc. (MNPR)vs › | $507.55M | -13.22% | -17.80% | -57.37% | -51.87% |
| 908 Devices Inc. (MASS)vs › | $513.25M | -17.46% | -32.28% | -24.08% | -18.67% |
| Altimmune, Inc. (ALT)vs › | $516.46M | -17.40% | -49.85% | -45.66% | -41.17% |
| Immix Biopharma, Inc. (IMMX)vs › | $521.76M | -16.69% | -61.13% | -63.72% | -100.27% |
| Evolus, Inc. (EOLS)vs › | $473.57M | -13.84% | -22.27% | -29.75% | -35.86% |
| Bright Minds Biosciences Inc. (DRUG)vs › | $473.36M | -8.14% | -30.20% | -72.84% | -64.85% |
| Arvinas, Inc. (ARVN)vs › | $471.65M | 1.38% | -14.74% | -19.98% | -18.10% |
| Contineum Therapeutics, Inc. (CTNM)vs › | $471.20M | -22.99% | -20.77% | -18.00% | -22.63% |
| Crescent Biopharma, Inc. (CBIO)vs › | $531.34M | -89.18% | -100.15% | -92.96% | -79.13% |
ROA
-30.1%
ROE
-37.9%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -45.90% |
| 2024-12-31 | -46.94% |
| 2023-12-31 | -50.91% |
| 2022-12-31 | -41.43% |
| 2021-12-31 | -17.32% |
| 2020-12-31 | -20.38% |
| 2019-12-31 | -25.72% |
| 2018-12-31 | -27.33% |
| 2017-12-31 | 0.00% |
